Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXO-CD24 in Moderate/Severe COVID-19
NCT04747574Phase 1Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Sep 2020
- Primary completion
- Feb 2021
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of exosomes overexpressing CD24 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoint: Adverse events at 35 days. Status: unknown.
02
Drugs
exosomes overexpressing CD24
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04747574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04747574.